Alpha-Synuclein PET/CT in Various α-Syn-Related Disease

Launched by TIANJIN MEDICAL UNIVERSITY · Apr 22, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a special type of imaging called PET/CT scans using new substances to see how they can help diagnose diseases related to a protein called alpha-synuclein, which is linked to conditions like Parkinson's Disease. The goal is to understand if these scans can effectively identify both primary (the original) and metastatic (spread) lesions in patients who may have these alpha-synuclein-related diseases.

To participate, you need to be an adult aged 18 or older with suspected or newly diagnosed Parkinson's Disease, and you should have already scheduled a PET/CT scan. You must also be able to give consent, which means you agree to participate in the study. Unfortunately, people who are pregnant or have certain other conditions are not eligible. If you join the trial, you'll receive the PET/CT scans and help researchers learn more about these diseases, which could lead to better diagnosis and treatment in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated PD (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled α-Syn PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
• Exclusion Criteria:
• • (i) patients with none PD syndrome; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.